In spite of the lack of structural studies characterizing Gal-3/G3-C12 peptide binding, this peptide seems to be very promising not only as Gal-3-targeted imaging agent but also as therapeutic agent for Gal-3-overexpressing cancers such as melanoma and breast, ovarian, and gastric carcinomas (154). The gene discussed is LGALS3; the disease is cancer.